Drug Trial Radar · NCT01197755
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Last checked: Nov 20, 2026Latest source record: Apr 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
323
Actual
Start
Sep 2010
Primary completion
Feb 2013
Study completion Feb 2013
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate and have had an inadequate response to a single TNF-alpha antagonist. The study will last for approximately six months.
Conditions
- Rheumatoid Arthritis
Interventions
fostamatinibDrug
fostamatinib 100 mg twice daily
fostamatinibDrug
fostamatinib 100 mg twice daily/150 mg once daily
placeboDrug
Placebo twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients Achieving ACR20 at Week 24, Comparison Between Fostamatinib and PlaceboTime frame: 24 weeks
Locations
135 sites in 16 countries. Site status is shown where the registry gives one.
Research Site
Anniston, Alabama
Research Site
Huntsville, Alabama
Research Site
Tuscaloosa, Alabama
Research Site
Mesa, Arizona
Research Site
Scottsdale, Arizona
Research Site
Hot Springs, Arkansas
Research Site
Glendale, California
Research Site
La Jolla, California
Research Site
Long Beach, California
Research Site
Palo Alto, California
Research Site
Santa Maria, California
Research Site
Torrance, California
Research Site
Tustin, California
Research Site
Upland, California
Research Site
Colorado Springs, Colorado
Research Site
Bridgeport, Connecticut
Research Site
Trumbull, Connecticut
Research Site
Lewes, Delaware
Research Site
Brandon, Florida
Research Site
Jacksonville, Florida
Research Site
Ocala, Florida
Research Site
Orlando, Florida
Research Site
Tampa, Florida
Research Site
Venice, Florida
Research Site
Zephyrhills, Florida
Research Site
Atlanta, Georgia
Research Site
Canton, Georgia
Research Site
Idaho Falls, Idaho
Research Site
Decatur, Illinois
Research Site
Cedar Rapids, Iowa
Research Site
Bowling Green, Kentucky
Research Site
Elizabethtown, Kentucky
Research Site
Crofton, Maryland
Research Site
Fall River, Massachusetts
Research Site
Worcester, Massachusetts
Research Site
Lansing, Michigan
Research Site
Flowood, Mississippi
Research Site
Florissant, Missouri
Research Site
Richmond Heights, Missouri
Research Site
Las Cruces, New Mexico
Showing 40 of 135 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.